July 9th, 2009
The Washington consensus on drugs rests on two widely shared beliefs. The first is that the war on drugs is a failure. The second is that it cannot be changed.
Americans are a can-do people. They tend to believe that if something does not work, it needs to be fixed. Unless, that is, they are talking about the war on drugs. On this politically fraught issue, Washington’s elites and, indeed, the majority of the population, believe two contradictory things. First, 76 percent of Americans think the war on drugs launched in 1971 by President Richard Nixon has failed. Yet only 19 percent believe the central focus of antidrug efforts should be shifted from interdiction and incarceration to treatment and education. A full 73 percent of Americans are against legalizing any kind of drugs, and 60 percent oppose legalizing marijuana.
This “it doesn’t work, but don’t change it” incongruity is not just a quirk of the U.S. public. It is a manifestation of how the prohibition on drugs has led to a prohibition on rational thought. “Most of my colleagues know that the war on drugs is bankrupt,” a U.S. senator told me, “but for many of us, supporting any form of decriminalization of drugs has long been politically suicidal.”
As a result of this utter failure to think, the United States today is both the world’s largest importer of illicit drugs and the world’s largest exporter of bad drug policy. The U.S. government expects, indeed demands, that its allies adopt its goals and methods and actively collaborate with U.S. drug-fighting agencies. This expectation is one of the few areas of rigorous continuity in U.S. foreign policy over the last three decades.
A second, and more damaging, effect comes from the U.S. emphasis on curtailing the supply abroad rather than lowering the demand at home. The consequence: a transfer of power from governments to criminals in a growing number of countries. In many places, narcotraffickers are the major source of jobs, economic opportunity, and money for elections.
The global economic crisis will only intensify these trends as battered economies shrink and illicit trade becomes the only way for millions of people to make a living. Mexico’s attorney general reckons that U.S. consumers buy $10 billion worth of drugs from his country’s cartels each year, a business that propelled Joaquín “El Chapo” Guzmán Loera, the leader of the Sinaloa cartel, to Forbes magazine’s latest list of the world’s billionaires. According to the U.S. Department of Defense, all that money allows the two main cartels to train, equip, and pay for a highly motivated army of 100,000 that almost equals Mexico’s armed forces in size and often outguns them. And this ascendancy of the drug cartels is a global problem. The opium trade is equal to 30 percent of Afghanistan’s legal economy, and from Burma to Bolivia, Moldova to Guinea-Bissau, drug kingpins have become influential economic and political actors.
Fortunately, there are some signs that the blind support for prohibition is beginning to wane among key Washington elites. One surprising new convert? The Pentagon. Senior U.S. military officers know both that the war on drugs is bankrupt and that it is undermining their ability to succeed in other important missions, such as winning the war in Afghanistan. When Gen. James L. Jones, a former Marine Corps commandant and supreme allied commander in Europe, was asked last November why the United States was losing in Afghanistan, he answered: “The top of my list is the drugs and narcotics, which are, without question, the economic engine that fuels the resurgent Taliban, and the crime and corruption in the country. . . . We couldn’t even talk about that in 2006 when I was there. That was not a topic that anybody wanted to talk about, including the U.S.” Jones is now U.S. President Barack Obama’s national security advisor.
But such views have set off fierce clashes between military commanders newly focused on creating peaceful economic opportunities for Afghan families and the U.S. drug warriors set on eradicating Afghanistan’s major cash crop at any cost. What’s more, inertia alone almost guarantees strong support for drug eradication from the massive bureaucracy that lives off the tens of billions of taxpayer dollars that have funded the war on drugs for decades. The opinions of these drug warriors are immune to data: After decades of eradication efforts around the world, neither the acreage of land used to grow drugs nor the tonnage produced has shrunk.
But prohibition at any cost is becoming increasingly hard to defend. As the drug-fueled escalation of violence in Mexico spills across the border into the United States, the American public’s willingness to ignore or tolerate policies that don’t work is bound to decline. And the consequences of failure are already on mounting display: According to the U.S. National Drug Intelligence Center, Mexican drug cartels have established operations in 195 American cities. It is much harder to ignore the collateral damage of the war on drugs when it happens in your neighborhood.
That is the case in many other countries where the nefarious side effects of U.S. drug policies have long been felt. Three of Latin America’s most respected former presidents, Brazil’s Fernando Henrique Cardoso, Colombia’s César Gaviria, and Mexico’s Ernesto Zedillo, recently chaired a commission that came out in favor of drastic changes in the war on drugs—including decriminalization of marijuana for personal use. The commission, on which I sat, spent more than a year reviewing the best available evidence from experts in public health, medicine, law enforcement, the military, and the economics of drug trafficking. One of the commission’s main conclusions is that governments urgently need options beyond eradication, interdiction, criminalization, and incarceration to limit the social consequences of drugs. But though smart thinkers increasingly propose confronting the drug curse as a public health crisis—more options are in the commission’s report at www.drugsanddemocracy.org—real alternatives have found no space in a policy debate stalemated between absolute prohibition and wholesale legalization.
The addiction to a failed policy has long been fueled by the self-interest of a relatively small prohibitionist community—and enabled by the distraction of the American public. But as the costs of the drug war spread from remote countries and U.S. inner cities to the rest of society, spending more to cure and prevent than to eradicate and incarcerate will become a much more obvious idea. Smarter thinking on drugs? That should be the real no-brainer.
Moisés Naím is editor in chief of Foreign Policy.
Similar posts: smoking with depakote
Americans are a can-do people. They tend to believe that if something does not work, it needs to be fixed. Unless, that is, they are talking about the war on drugs. On this politically fraught issue, Washington’s elites and, indeed, the majority of the population, believe two contradictory things. First, 76 percent of Americans think the war on drugs launched in 1971 by President Richard Nixon has failed. Yet only 19 percent believe the central focus of antidrug efforts should be shifted from interdiction and incarceration to treatment and education. A full 73 percent of Americans are against legalizing any kind of drugs, and 60 percent oppose legalizing marijuana.
This “it doesn’t work, but don’t change it” incongruity is not just a quirk of the U.S. public. It is a manifestation of how the prohibition on drugs has led to a prohibition on rational thought. “Most of my colleagues know that the war on drugs is bankrupt,” a U.S. senator told me, “but for many of us, supporting any form of decriminalization of drugs has long been politically suicidal.”
As a result of this utter failure to think, the United States today is both the world’s largest importer of illicit drugs and the world’s largest exporter of bad drug policy. The U.S. government expects, indeed demands, that its allies adopt its goals and methods and actively collaborate with U.S. drug-fighting agencies. This expectation is one of the few areas of rigorous continuity in U.S. foreign policy over the last three decades.
A second, and more damaging, effect comes from the U.S. emphasis on curtailing the supply abroad rather than lowering the demand at home. The consequence: a transfer of power from governments to criminals in a growing number of countries. In many places, narcotraffickers are the major source of jobs, economic opportunity, and money for elections.
The global economic crisis will only intensify these trends as battered economies shrink and illicit trade becomes the only way for millions of people to make a living. Mexico’s attorney general reckons that U.S. consumers buy $10 billion worth of drugs from his country’s cartels each year, a business that propelled Joaquín “El Chapo” Guzmán Loera, the leader of the Sinaloa cartel, to Forbes magazine’s latest list of the world’s billionaires. According to the U.S. Department of Defense, all that money allows the two main cartels to train, equip, and pay for a highly motivated army of 100,000 that almost equals Mexico’s armed forces in size and often outguns them. And this ascendancy of the drug cartels is a global problem. The opium trade is equal to 30 percent of Afghanistan’s legal economy, and from Burma to Bolivia, Moldova to Guinea-Bissau, drug kingpins have become influential economic and political actors.
Fortunately, there are some signs that the blind support for prohibition is beginning to wane among key Washington elites. One surprising new convert? The Pentagon. Senior U.S. military officers know both that the war on drugs is bankrupt and that it is undermining their ability to succeed in other important missions, such as winning the war in Afghanistan. When Gen. James L. Jones, a former Marine Corps commandant and supreme allied commander in Europe, was asked last November why the United States was losing in Afghanistan, he answered: “The top of my list is the drugs and narcotics, which are, without question, the economic engine that fuels the resurgent Taliban, and the crime and corruption in the country. . . . We couldn’t even talk about that in 2006 when I was there. That was not a topic that anybody wanted to talk about, including the U.S.” Jones is now U.S. President Barack Obama’s national security advisor.
But such views have set off fierce clashes between military commanders newly focused on creating peaceful economic opportunities for Afghan families and the U.S. drug warriors set on eradicating Afghanistan’s major cash crop at any cost. What’s more, inertia alone almost guarantees strong support for drug eradication from the massive bureaucracy that lives off the tens of billions of taxpayer dollars that have funded the war on drugs for decades. The opinions of these drug warriors are immune to data: After decades of eradication efforts around the world, neither the acreage of land used to grow drugs nor the tonnage produced has shrunk.
But prohibition at any cost is becoming increasingly hard to defend. As the drug-fueled escalation of violence in Mexico spills across the border into the United States, the American public’s willingness to ignore or tolerate policies that don’t work is bound to decline. And the consequences of failure are already on mounting display: According to the U.S. National Drug Intelligence Center, Mexican drug cartels have established operations in 195 American cities. It is much harder to ignore the collateral damage of the war on drugs when it happens in your neighborhood.
That is the case in many other countries where the nefarious side effects of U.S. drug policies have long been felt. Three of Latin America’s most respected former presidents, Brazil’s Fernando Henrique Cardoso, Colombia’s César Gaviria, and Mexico’s Ernesto Zedillo, recently chaired a commission that came out in favor of drastic changes in the war on drugs—including decriminalization of marijuana for personal use. The commission, on which I sat, spent more than a year reviewing the best available evidence from experts in public health, medicine, law enforcement, the military, and the economics of drug trafficking. One of the commission’s main conclusions is that governments urgently need options beyond eradication, interdiction, criminalization, and incarceration to limit the social consequences of drugs. But though smart thinkers increasingly propose confronting the drug curse as a public health crisis—more options are in the commission’s report at www.drugsanddemocracy.org—real alternatives have found no space in a policy debate stalemated between absolute prohibition and wholesale legalization.
The addiction to a failed policy has long been fueled by the self-interest of a relatively small prohibitionist community—and enabled by the distraction of the American public. But as the costs of the drug war spread from remote countries and U.S. inner cities to the rest of society, spending more to cure and prevent than to eradicate and incarcerate will become a much more obvious idea. Smarter thinking on drugs? That should be the real no-brainer.
Moisés Naím is editor in chief of Foreign Policy.
Similar posts: smoking with depakote
- Mood:Good
- Music:Linkin Park
Chinese herbal medicine for endometriosis
Flower A, Liu JP, Chen S, Lewith G, Little P
Chinese herbs for endometriosis
Endometriosis is a common gynaecological condition causing menstrual and pelvic pain. Treatment involves surgery and hormonal drugs, with potentially unpleasant side effects and high rates of reoccurrence of endometriosis. This review suggests that Chinese herbal medicine (CHM) may be useful in relieving endometriosis-related pain with fewer side effects than experienced with conventional treatment. However, the two trials included in this review are of poor methodological quality so these findings must be interpreted cautiously. Better quality randomised controlled trials are needed to investigate a possible role for CHM in the treatment of endometriosis.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2009 Issue 3, Copyright © 2009 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This record should be cited as: Flower A, Liu JP, Chen S, Lewith G, Little P. Chinese herbal medicine for endometriosis. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD006568. DOI: 10.1002/14651858.CD006568.pub2
This version first published online: July 08. 2009
Abstract
Background
Endometriosis is characterized by the presence of tissue that is morphologically and biologically similar to normal endometrium in locations outside the uterus. Surgical and hormonal treatment of endometriosis have unpleasant side effects and high rates of relapse. In China, treatment of endometriosis using Chinese herbal medicine (CHM) is routine and considerable research into the role of CHM in alleviating pain, promoting fertility, and preventing relapse has taken place.
Objectives
To review the effectiveness and safety of CHM in alleviating endometriosis-related pain and infertility.
Search strategy
We searched the Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library) and the following English language electronic databases (from their inception to the present): MEDLINE, EMBASE, AMED, CINAHL, NLH on the 30/04/09.
We also searched Chinese language electronic databases: Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Sci Tech Journals (VIP), Traditional Chinese Medical Literature Analysis and Retrieval System (TCMLARS), and Chinese Medical Current Contents (CMCC).
Selection criteria
Randomised controlled trials (RCTs) involving CHM versus placebo, biomedical treatment, another CHM intervention, or CHM plus biomedical treatment versus biomedical treatment were selected. Only trials with confirmed randomisation procedures and laparoscopic diagnosis of endometriosis were included.
Data collection and analysis
Risk of bias assessment, and data extraction and analysis were performed independently by three review authors. Data were combined for meta-analysis using relative risk (RR) for dichotomous data. A fixed-effect statistical model was used, where appropriate. Data not suitable for meta-analysis are presented as descriptive data.
Main results
Two Chinese RCTs involving 158 women were included in this review. Both these trials described adequate methodology. Neither trial compared CHM with placebo treatment.
There was no evidence of a significant difference in rates of symptomatic relief between CHM and gestrinone administered subsequent to laparoscopic surgery (95.65% versus 93.87%; risk ratio (RR) 1.02, 95% confidence interval (CI) 0.93 to 1.12, one RCT). The intention-to-treat analysis also showed no significant difference between the groups (RR 1.04, 95% CI 0.91 to 1.18). There was no significant difference between the CHM and gestrinone groups with regard to the total pregnancy rate (69.6% versus 59.1%; RR 1.18, 95% CI 0.87 to 1.59, one RCT).
CHM administered orally and then in conjunction with a herbal enema resulted in a greater proportion of women obtaining symptomatic relief than with danazol (RR 5.06, 95% CI 1.28 to 20.05; RR 5.63, 95% CI 1.47 to 21.54, respectively).
Overall, 100% of women in all the groups showed some improvement in their symptoms.
Oral plus enema administration of CHM showed a greater reduction in average dysmenorrhoea pain scores than did danazol (mean difference (MD) -2.90, 95% CI -4.55 to -1.
Similar posts: medicine library
Flower A, Liu JP, Chen S, Lewith G, Little P
Chinese herbs for endometriosis
Endometriosis is a common gynaecological condition causing menstrual and pelvic pain. Treatment involves surgery and hormonal drugs, with potentially unpleasant side effects and high rates of reoccurrence of endometriosis. This review suggests that Chinese herbal medicine (CHM) may be useful in relieving endometriosis-related pain with fewer side effects than experienced with conventional treatment. However, the two trials included in this review are of poor methodological quality so these findings must be interpreted cautiously. Better quality randomised controlled trials are needed to investigate a possible role for CHM in the treatment of endometriosis.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2009 Issue 3, Copyright © 2009 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This record should be cited as: Flower A, Liu JP, Chen S, Lewith G, Little P. Chinese herbal medicine for endometriosis. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD006568. DOI: 10.1002/14651858.CD006568.pub2
This version first published online: July 08. 2009
Abstract
Background
Endometriosis is characterized by the presence of tissue that is morphologically and biologically similar to normal endometrium in locations outside the uterus. Surgical and hormonal treatment of endometriosis have unpleasant side effects and high rates of relapse. In China, treatment of endometriosis using Chinese herbal medicine (CHM) is routine and considerable research into the role of CHM in alleviating pain, promoting fertility, and preventing relapse has taken place.
Objectives
To review the effectiveness and safety of CHM in alleviating endometriosis-related pain and infertility.
Search strategy
We searched the Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library) and the following English language electronic databases (from their inception to the present): MEDLINE, EMBASE, AMED, CINAHL, NLH on the 30/04/09.
We also searched Chinese language electronic databases: Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Sci Tech Journals (VIP), Traditional Chinese Medical Literature Analysis and Retrieval System (TCMLARS), and Chinese Medical Current Contents (CMCC).
Selection criteria
Randomised controlled trials (RCTs) involving CHM versus placebo, biomedical treatment, another CHM intervention, or CHM plus biomedical treatment versus biomedical treatment were selected. Only trials with confirmed randomisation procedures and laparoscopic diagnosis of endometriosis were included.
Data collection and analysis
Risk of bias assessment, and data extraction and analysis were performed independently by three review authors. Data were combined for meta-analysis using relative risk (RR) for dichotomous data. A fixed-effect statistical model was used, where appropriate. Data not suitable for meta-analysis are presented as descriptive data.
Main results
Two Chinese RCTs involving 158 women were included in this review. Both these trials described adequate methodology. Neither trial compared CHM with placebo treatment.
There was no evidence of a significant difference in rates of symptomatic relief between CHM and gestrinone administered subsequent to laparoscopic surgery (95.65% versus 93.87%; risk ratio (RR) 1.02, 95% confidence interval (CI) 0.93 to 1.12, one RCT). The intention-to-treat analysis also showed no significant difference between the groups (RR 1.04, 95% CI 0.91 to 1.18). There was no significant difference between the CHM and gestrinone groups with regard to the total pregnancy rate (69.6% versus 59.1%; RR 1.18, 95% CI 0.87 to 1.59, one RCT).
CHM administered orally and then in conjunction with a herbal enema resulted in a greater proportion of women obtaining symptomatic relief than with danazol (RR 5.06, 95% CI 1.28 to 20.05; RR 5.63, 95% CI 1.47 to 21.54, respectively).
Overall, 100% of women in all the groups showed some improvement in their symptoms.
Oral plus enema administration of CHM showed a greater reduction in average dysmenorrhoea pain scores than did danazol (mean difference (MD) -2.90, 95% CI -4.55 to -1.
Similar posts: medicine library
- Mood:normal
- Music:Limp Bizkit
We have gotten a dog (half rottweiler, half lab) that has been in the family for five years. We are now the primary care takers of this beautiful dog and couldnt be happier!
We havent had a dog per say, only three cats, so the whole dog thing is new, especially concerning health aspects.
His and even his have really dry, course, rough skin, apparently from where he has laid on them for his life. Any advice on what to put on it? It looks like it is sore, but I doubt it bothers him. I was thinking D Ointment which is usually used to treat rashes, or Vitamin E capsules any advice would be appreciated! Thanks.
Similar posts: acne medicine
We havent had a dog per say, only three cats, so the whole dog thing is new, especially concerning health aspects.
His and even his have really dry, course, rough skin, apparently from where he has laid on them for his life. Any advice on what to put on it? It looks like it is sore, but I doubt it bothers him. I was thinking D Ointment which is usually used to treat rashes, or Vitamin E capsules any advice would be appreciated! Thanks.
Similar posts: acne medicine
- Mood:normal
- Music:Black Eyed Peas
There are two additional issues I would like to highlight today that are not addressed by the Committee bill that we believe should be considered. The first is the offense of material support for terrorism or terrorist groups. While this is a very important offense in our counterterrorism prosecutions in Federal court under title 18 of the U.S. Code, there are serious questions as to whether material support for terrorism or terrorist groups is a traditional violation of the law of war. The President has made clear that military commissions are to be used only to prosecute law of war offenses. Although identifying traditional law of war offenses can be a difficult legal and historical exercise, our experts believe that there is a significant risk that appellate courts will ultimately conclude that material support for terrorism is not a traditional law of war offense, thereby reversing hard-won convictions and leading to questions about the system’s legitimacy. However, we believe conspiracy can, in many cases, be properly charged consistent with the law of war in military commissions, and that cases that yield material support charges could often yield such conspiracy charges. Further, material support charges could be pursued in Federal court where feasible.
Similar posts: support breast cancer
Similar posts: support breast cancer
- Mood:Good
- Music:PaPa RoAch
